NTD Conference Handouts Houston 2012-06-07 Ab

Baylor College ofMedicine

The National School of Tropical Medicine (NSTM) is the rst school in the UnitedStates solely committed to addressing the world’s most pressing tropical disease issues.The school applies the knowledge of the strong traditions in basic, translational andapplied biotechnology research and clinical care to launch a variety ofeducationalprograms. The NSTM will train a new generation of scientists and health professionals to address the need to diagnose, prevent and treat the world’s most importantNeglected Tropical Diseases (NTDs) and Neglected Infections of Poverty (NIoPs)—diseases which both initiate and perpetuate poverty.

The Mission of the National School of Tropical Medicine is to:

Train the next generation of global health scientists and global health careproviders in the area of tropical medicine

o Discover, develop and deliver a new generation of appropriate global healthtechnologies, i.e., vaccines, drugs, and diagnostics, for the world’s majortropical diseases, NTDs, malaria, and other neglected infections of poverty

Establish and enhance capabilities to treat and prevent NTDs, NIoPs andmalaria in Texas

Provide training that will lead to the shaping of public policy around thedelivery of new and appropriate technologies for tropicaldiseases affecting the poorest people in low income countries

EH5‘ *.|§1For more information visit _ Iwww.bcm.edu/tr opioalmedioine . _

01'emaill§|"DpIT|[email protected] E. " '

\'rMTexas Children’s

Hospitall

The Product Development Partnership (PDP) of the Sabin Vaccine Institute,headquartered in Washington, DC, established its new Houston of ce in the TexasChildren’s Hospital Feigin Center, at the heart of the Texas Medical Center (TMC). Inpartnership with Texas Children’s Hospital, the new Sabin Vaccine Institute and TexasChildren’s Hospital Center for Vaccine Development was established to strengthen theSabin PDP and further its mission ofadvancing collaborations in the eld ofvaccineand global health biotechnology in response to the burden caused by Neglected TropicalDiseases (NTDs) in the global community.

The Center for Vaccine Development is establishing strong ties within the TMC andis exploring a range of research programs and initiatives to address challenges in thediagnosis, prevention and treatment ofsome of the world’s most devastating infectiousand parasitic diseases. These will include new platforms for the design and developmentofnew diagnostics, drugs and vaccines from the bench into the clinic and the development ofnew scienti c inquiries through basic, translational and clinical research thatwill signi cantly advance the available body ofknowledge for these destructive diseases.

For more information, email t|"O|JlT|BC|@bGm.8Cl U

Q VACCINE INSTITUTE

| Svriccirve irvsrrrure

. RE_SEAFiC_l"l ADVOCACY IMPACT l

The Need\/aqginggg are (me of pubis; health’; mo; r powerful t()()|5 other diseases in order to achieve these returns, however Sabinand currently save over three rriiliion young lives each yearin the developing world. However, reliance on traditionalpharmaceutical companies to develop vaccines for infectiousand neglected tropical diseases (NTDs) that affect the poor hasbeen unsuccessful. Alternative funding strategies are needed todevelop vaccines that will bene t the vvorld’s bottom billion.

Our WorkAs part ofa new affiliation with Baylor College of Medicine (BCl\/lland Texas Chiidren's Hospital (TCH), the Sabin Vaccine institutePDP recently relocated to bra nd new iaboratory space at theTexas Medical Center in Houston, Texas. Supported by significantnew funding from BCM and TCH, and in collaboration withpartners including Fundacao Osvvaldo Cruz, lnstituto Butantan,and The George Washington University, the Sabin PDP continuesto develop safe, effective, and lovv cost vaccines that vvlli bene tunderserved populations of developing nations.

Sabin PDP's i "i years of research and deveioprnent experiencehas produced a vveli rounded, low cost rnodel that serves as ablueprint for vaccine cleveioprnent and ongoing efforts to ghtpublic health threats that adversely impact more than one billionpeople worldwide living on less than $i.25 per day.

Recent progress in vaccine research and strengthening of localpartnerships in Brazil has prove rt that this model works and hasthe potential to be expanded into other regions and to "address

' "§=i§‘:zl§;‘; . .l._, : §Ij§5;

PDP requires signi cant investment A single piece of laboratoryequipment can cost up to $iOO O00 while Phasei clinical trialscan cost Si rniliion over two years Sabin seeks new partnersfor investment ll"! current and new vaccine developmentopportunities together we will bring lasting change to thosemost in need

The ImpactHookvvorm, schistosomiasis, and Chagas disease together affectnearly one billion people worldwide Success in achieving costeffective vaccines for these three diseases alone would preventthe deaths of hundreds of thousands annually and the sufferingof rnilirons more This would not oniy leave affected populationsheaithrer, it vvoiiid also provide econornic and educationaireturns, as children vvouid be less likely to miss school and adultworker productivity would increase

Our VisionThe Sabin PDP has established a unique framework for the nonpro t developinent of vaccines and lS an essential element ofthe Sabin Vaccine institutes mission to reduce hurnan sufferingcaused by infectious diseases and NTDs In partnership withadditional vaccine developers, we can rnake a lasting impact onthe WOl'lClWiCl€:‘ burden of infectious diseases and NT[)s

~d\""Y{WH\rv\¢¢>uvnvv\vnwv\Ivvrvvv4\|\\v\ \M.uu\. v ,.\».\.. M» \ \».. M.»

§

forhuman hookwerm infection A human_ ' 'ifrfo'rEdvvrde, currently estimated at more thanffmiiiion, and a'l'lo“ni":them" rte.i"€3.r§;li:,i1ihe‘§ ll ?lr;ili._. p_osiiIi's fiel§., .='=‘S‘afi§i§in§5',has" two '1hookworm vaccine candidates scheduled

_ I Phaset ,_

i

iii

. Sabin a deadly disease affecting

ii§*"7§§I 3~?Si'll3.r**1f1'i,i,liSi¥€1*?ii héii lliéiicsileetleniide viii disease, liver and biaiider cancers and1 p i55

60236».S I. I reserve fer Chases sin ease thatIn . vvilibe people are infected with this

_ s

_ i . __...__ <1

l Global Health Research and Development and the Hidden Burden

{ Agenda:

ofNeglected Tropical Diseases in Texas A

Date: Thursday, June 7, 2012

Panel Moderator: Karen A. Goraleski

9:00 am. 9:30 am. Breakfast

9:30 am. 9:45 a.m. Opening RemarksPeter ]. Hotez

9:45 am. 10:30 am. Plenary lecture: Fifty years of global health in Africa, Asia, Latin America, and Texas!Ioseph McCormick

10:30 am. 12: 10 p.m. Panel Discussion: Landscape ofNegleeted Diseases in Texas and Mesoamerica

10:30 a.m. 11:20 a.rn. Neglected Parasitic DiseasesPeter Melby; Sue Montgomery; Jesus Valenzuela

11:20 a.m. 12:10 p.m. Neglected Viral and Bacterial Diseases

12:10 p.m. 1:00 p.rn.

1:00 p.m. 1:40 p.m

. 1:40 p.m. 2:30 p.m

2:30 p.111. 3:00 p.m

3:15p.m. 4:30p.m

I:

Susan Fisher Hoch; Harold Margolis; Kristy Murray

Lunch at Rayzor Lounge

Lunchtime Plenary Lecture: From NTD treatment to prevention: The path towardsvaccine introduction in the Americas

Ion Andrus

Panel Discussion: New Tools and the Strategies for Their Development:Partnerships, Funding, and Texas Research

Maria Elena Bottazzi; Bruce Lee; Rebecca Rico Hesse

Closing RemarksPeter]. Hotez

Reception at Trevisio Restaurant hosted in collaboration with Texas Children’sHospital and Baylor College of Medicine

Partners for this event include:9‘ View; / ..‘___‘_ 05A B | N BCM

Q vaccme l|‘\JS'?"‘TLiTE 0

M RESEARCH‘r ‘v » 5Texas Children’s E R

O

“awo\.r4(' Q9)) 5.,*1‘ ~"~::oat‘ft; ;etf T" Baylor College 0fMed1c1nc

'l¥lFlf_'IT?

1/H I‘ AN ALLIANCE ma olscovuzlts IN Iuzatm‘ \{H: ‘ 45;?

Advancmg global health Smce 19 03

0

E

a .

‘L.

\

Jon Anoaus, MDDEPUTY DIRECTOR, PAN AMERICAN HEALTH ORGANIZATIONDr. Jon Kim Andrus is the Deputy Director of the Pan American Health Organization. Dr. Andrus also servesas the Principle Investigator of PAHO’s Provac Initiative to enhance national capacity to make evidencebased decisions for the introduction of new vaccines. In 2000, Dr. Andrus received the DistinguishedService Medal of the United States Public Health Service for leadership for working to eradicate polio inSouth East Asia. In 2007, he received the Philip R. Horne Award for sustained worldwide leadership in theglobal and regional immunization initiatives to eradicate polio, eliminate measles and rubella, and for thecontrol of other vaccine preventable diseases. He has published numerous scientific articles on vaccines,immunization, and accelerated control of vaccine preventable diseases. He holds faculty appointments atGeorge Washington University and University California San Francisco School of Medicine.

MARIA ELENA BOTTAZZI, PHDDIRECTOR, PRODUCT DEVELOPMENT, SABIN VACCINE INSTITUTE ANDTEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT,BAYLOR COLLEGE or MEDICINEMaria Elena Bottazzi, Ph.D. is the associate dean of the National School of Tropical Medicine and aprofessor of pediatrics at Baylor College of Medicine. She also directs research and administrativeactivities of BCM's new Section of Pediatric Tropical Medicine and she leads product development for theSabin vaccine development program at Texas Children's Hospital and BCM.

Bottazzi previously was associate professor and vice chair for administration in the Department ofMicrobiology, Immunology and Tropical Medicine at George Washington University.

Bottazzi is an internationally recognized scientist with more than 10 years of experience in translationalresearch and vaccine development for neglected tropical diseases. In addition, her major interest is therole of vaccines as control tools in international public health programs and initiatives.

She is a native of Tegucigalpa, Honduras, where she obtained her degree in microbiology and clinicalchemistry in 1989, followed by her Ph.D. in molecular immunology and experimental pathology at theUniversity of Florida in Gainesville in 1995. Her post doctoral training in cellular biology was completed1995 2001 at the University of Miami and the University of Pennsylvania. She became an assistantprofessor in 2001 after moving to the George Washington University.

Bottazzi is an associate for the Public Library of Science (PLoS) Neglected Tropical Disease Journal and isthe author or co author of more than 60 scientific and technical papers in molecular, cellular biology,immunoparasitology, and vaccine development. She is the recipient of multiple awards and was recentlyappointed as a member of the International Advisory Committee of the Carlos Slim Health Institute inMexico.

SUSAN FISHER HOCH, MDPROFESSOR, DEPARTMENT or EPIDEMIOLOGY, BAYLOR COLLEGE orMEDICINESue Fisher Hoch was born in England in 1940. She gained admission to the Royal Free Hospital School ofMedicine in 1970. By 1981 she had membership of the Royal College of Pathology in Virology, a Master'sdegree in Microbiology with distinction and a doctoral degree in epidemiology (MD) from LondonUniversity. "Her doctoral thesis findings were published in the Lancet and were the first i'd'entification ofhot water systems as the source of outbreaks of Legionnaire’.s disease, as opposed to air conditioning.She was also central to the discovery that the parvovirus B19 was responsible for Fifth’s Disease, and inthe first identification of E.coli 0157 as the cause of hemolytic uremic syndrome. In 1984 she was invitedto the CDC, Atlanta space suit BSL4 laboratory and published her findings on Lassa fever virus in the

0

‘ii.<.~:".

L’

Journal of Infectious Diseases, providing key information on the pathophysiology of Ebola and Lassaviruses. In 1986 she moved permanently to CDC where she remained for eight years, becoming DeputyBranch Chief, Special Pathogens Laboratory, Division of Viral Diseases, and serving as Acting Branch Chief.

In 1993 she moved to the Aga Khan University, Karachi, Pakistan and supervised the Clinical MicrobiologyLaboratory, the largest in Pakistan. She established a molecular biology research laboratory, and workedand published studies on pathogens such as hepatitis C, Congo Crimean Hemorrhagic Fever, tuberculosis,typhoid and cholera. In 1997 she and her husband moved to Lyon, France, where she took charge of thedesign, building and scientific program of a new BSL4 space suit laboratory. Dr Fisher Hoch was awardedthe Chevalier de Legion d'Honneur by the President of France, Jacques Chirac, Le Medaille de Lyon by themayor and former Prime Minister of France, Raymond Barre, and Le Prix Scientifique du Group Paris~Lyon,for her work in designing, constructing, and rendering operational the BSL4 laboratory of Lyon. In January2001, she moved to Brownsville, Texas, with her husband to establish the new Brownsville campus of theUT School of Public Health. Here she has established a research program in diabetes and tuberculosisrecruiting and training a team of young scientists, mostly women, developing a large and extensivelydocumented ‘Framingham like’ cohort, the Cameron County Hispanic Cohort. This program has attractedsignificant NIH funding, and has made major advances in understanding of diseases in minoritypopulations. She has established a molecular microbiology laboratory, with a BSL3 for handlingpathogens such as Mycobacterium tuberculosis and West Nile Virus. In 2008 she was admitted to theWomen in Technology International Hall of Fame.

Dr. Fisher Hoch has over the years contributed many chapters to major textbooks, written review articles,reviewed for several journals, and has more than 160 major publications with more than 30 in the pastyear from her studies with the cohort. She has also worked recently in the interface of chronic andinfectious diseases, and is working with WHO and other international agencies to combat this newepidemic world wide. She has written invited editorials for the Lancet and The International Journal ofTuberculosis and Lung Disease, and provided expert advice to the lay press and television, being featuredpersonally in both media, and in books dealing with hemorrhagic fevers

KAREN A. GORALESKIEXECUTIVE DIRECTOR, AMERICAN SOCIETY or TROPICAL MEDICINEAND HYGIENEKaren Goraleski is Executive Director of the American Society of Tropical Medicine and Hygiene. ASTMH,located in Deerfield, Illinois, is a worldwide organization of scientists, clinicians, and programprofessionals whose mission is to promote global health through the prevention and control of infectiousand other diseases that disproportionately afflict the global poor. Research, health care and education arethe central activities of its members, whose work bridges basic research to international eld work andclinics to country wide programs.

Ms. Goraleski oversees all aspects of the Society’s efforts including the American Journal of TropicalMedicine and Hygiene, the CTropMed® Certificate of Knowledge in Clinical Tropical Medicine andTravelers‘ Health, the Annual Meeting that attracts a global audience and is widely considered thepremier meeting in tropical medicine and a portfolio of activities that includes awards and researchopportunities, policy development, advocacy, and membership.

Prior to joining ASTMH in 2010, Goraleski was Vice President of Public Health Partnerships atResearchlAmerica. She oversaw its global health research and domestic public health advocacy activities.A key strategy in these efforts was the development of targeted messages utilized by the organization'sextensive advocacy network.

An experienced presenter, knowledgeable in the translation of complex issues for decision makers, mediaand public, Goraleski has led national and local workshops for the science community that focus oninnovative advocacy using strategies designed to help non science audiences better understand the valueand importance of a strong U.S. investment in research.

Earlier positions included executive roles at the American Medical Association and the American HospitalAssociation. Ms. Goraleski received a Master of Social Work from the Jane Addams College of Social Workat the University of Illinois at Chicago and a Bachelor of Arts from St. Xavier University in Chicago.

r‘ _. '

' " _ x _.“Q__'

" _ , "I: l“"“1

. I ‘gal: _ _

,nm

‘I

J4_ itI >,; Atmt

In

5;I.iiii".._'.= = h"_ K’Pi ug, '1» ..'l'.“:'

REEEccA RICO HEssE, PHD, MPHSclENT1sT, TExAs BIOMEDICAL REsEARcH INSTITUTERebeca Rico Hesse, Ph.D., a scientist at the Southwest Foundation for Biomedical Research (SFBR), thismonth will be recognized by the Instituto Cultural de Mexico for her contributions to virology.

Rico Hesse is one of three women from Mexico recognized in celebration of the Centennial of theMexican Revolution and the Bicentennial of Mexico's Independence, and the acknowledgement ofInternational Women’s Month. The others are fashion designer Veronica Prida and artist Carla Veliz.

Rico Hesse obtained scholarships to study microbiology at the University of Nebraska, virology at CornellUniversity, epidemiology at the University of Minnesota, and post~doctoral training at the Centers forDisease Control in Atlanta. The Rockefeller Foundation funded her position as Assistant Professor at YaleUniversity, and her subsequent research funding has come from the National Institutes of Health. Shejoined the Southwest Foundation for Biomedical Research, in San Antonio, as a scientist, in 1996. She hasreceived many awards and recognitions for her research and publications.

Currently, Rico Hesse’s research is focused on dengue fever, a viral disease contracted by mosquito bite.During the last couple of centuries, the United States has suffered periodic outbreaks of dengue. Therehave been several recent outbreaks in South Texas. San Antonio is a port of entry into the rest of theUnited States because the climate allows for the type of mosquito that carries and transmits the disease.In its mild form, dengue causes what’s called break bone fever, with severe flu like symptoms. But thesevere, lethal form, dengue hemorrhagic fever, has increased steadily during the last decade, spreading toover 100 countries around the world.

PETER HoTEz, MD, PHDDEAN, NATIONAL ScHoo1. or TROPICAL MEDICINE, BAYLOR COLLEGEor ME|)1c1NEPeter J. Hotez, M.D., Ph.D., is the founding Dean of the National School of Tropical Medicine and Professorof Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine. He is also President ofthe Sabin Vaccine Institute and Director of the Texas Children’s Hospital Center for Vaccine Development.

Dr. Hotez is an internationally recognized clinician and investigator in neglected tropical diseases andvaccine development. He leads the only product development partnership for developing new vaccinesfor hookworm infection, schistosomiasis, and Chagas disease, diseases affecting hundreds of millions ofchildren and adults worldwide.

Dr. Hotez has authored more than 250 original papers, including lead articles in the New England Journalof Medicine, Lancet, Science, and Scientific American, and more than 30 op ed pieces or editorials,including pieces in the New York Times, LA Times, and the Washington Post and 61 textbook chapters. Hehas also authored or edited 10 books, including the acclaimed Forgotten People, Forgotten Diseases (ASMPress). He has been a frequently invited speaker or visiting professor and is a frequent contributor to theHuffington Post.

Dr. Hotez serves as the founding Editor in Chief of PLoS Neglected Tropical Diseases. He is a Fellow of theAmerican Academy of Pediatrics and the American Society of Tropical Medicine and Hygiene and hasserved in membership or leadership roles with a multitude of professional organizations, including as acurrent member of the NIH Council of Councils. He is an elected member of the Institute of Medicine(IOM) of the National Academy of Sciences and The Academy of Medicine, Engineering and Science ofTexas. In 2011 he was awarded the Abraham Horwitz Award for Excellence in Leadership in InterAmerican Health by the Pan American Health Organization of the WHO.

He currently serves as principal investigator for research grants from the Bill 81. Melinda Gates Foundation,the Dutch government, and NIH, as well as co principal investigator for a research grant from the CarlosSlim Health Institute.

1

I

,

'.

.I 1’III L

,.

r’.I' r itI Q _ ml) &

..__ ' .

rs J‘‘F ,;" X l

‘ IF 5

\' 6

\

'5 1 ~ ,,

BRUCE LEE, MD

Ass0cIATE PROFESSOR or MEDIcINE, EPIDEMIOLOGY, ANDBIOMEDICAL INEoRIvIATIcs, UNIVERSITY or PITTSBURGHBruce Y. Lee, MD, MBA is currently Associate Professor of Medicine, Epidemiology, and BiomedicalInformatics at the University of Pittsburgh School of Medicine and Graduate School of Public Health andCore Faculty for the RAND University of Pittsburgh Health Institute.

At the University of Pittsburgh, he directs the Public Health and Infectious Diseases Computational andOperations Research (PHICOR) group that specializes in designing economic, and operational computermodels that help decision makers tackle infectious diseases of global importance. He is the AppliedModeling Project Principal Investigator for the University of Pittsburgh National Institutes of Health (NIH)Modeling of Infectious Diseases Agent Study (MIDAS) National Center of Excellence. His current fundingalso includes grants from the Bill and Melinda Gates Foundation, the NIH, Centers for Disease Control andPrevention (CDC), National Science Foundation (NSF), National Library of Medicine (NLM), and thePennsylvania Department of Health.

His previous positions include serving as Senior Manager at Quintiles Transnational, working inbiotechnology equity research at Montgomery Securities, and co founding Integrigen, abiotechnology/bioinformatics company.

Dr. Lee has authored over 120 scientific publications (including over 70 first author and over 30 lastauthor) as well as three books: Principles and Practice of Clinical Trial Medicine, What If... ? : SurvivalGuide for Physicians, and Medical Notes: Clinical Medicine Pocket Guide.

Dr. Lee received his B.A. from Harvard University, M.D. from Harvard Medical School, and M.B.A. from theStanford Graduate School of Business. He is board certi ed in Internal Medicine, having completed hisresidency training at the University of California, San Diego.

HAROLD MARGOLIS, MDCHIEF, DENGUE BRANcH, CENTERs FOR DIsEAsE CONTROL ANDPREvENTI0NDr. Margolis received his MD from the University of Arizona, College of Medicine and completed apediatric residency at the University of Colorado Health Sciences Center. In 1975 he became an EpidemicIntelligence Service (EIS) Officer at CDC and remained with CDC where he directed the viral hepatitisresearch and prevention program from 1987 to 2004. In 2004, he became Director of the PediatricDengue Vaccine Initiative (PDVI), a program funded by the Bill and Melinda Gates Foundation at theInternational Vaccine Institute in Seoul, Korea. In 2010, Dr. Margolis returned to CDC as Chief of theDengue Branch in San Juan, Puerto Rico.

As director of CDC’s viral hepatitis program, Dr. Margolis had extensive experience in developing andimplementing prevention programs for diseases that affected both the United States and other countries.This included implementation of hepatitis A surveillance and immunization programs along US Mexicoborder. With the prospects of dengue becoming a vaccine preventable disease in the near future, Dr.Margolis is now leading efforts to obtain the data required to make appropriate recommendations forvaccine use in the US and neighboring countries affected by dengue.

Dr. Margolis is a fellow of the American Academy of Pediatrics (FAAP) and Infectious Disease Society ofAmerica (FIDSA). He is author or co author of over 200 peer reviewed publications.

““"?‘!‘m

]osEFH MCCORMICK, MDDIREcToR, CENTER FOR TROPICAL DIsEAsEs, UNIvERsITY OF TExAsMEDIcAL BRANcH (UTMB)Joseph B. McCormick, MD, MS is Vice President for South Texas Programs for the University of TexasHealth Science Center at San Antonio and the Regional Dean, Brownsville campus of the University ofTexas School of Public Health. He entered Duke Medical School in 1967 graduating in 1971 with anintercalated MS from Harvard School of Public Health (1970). His internship and residency were atChildren's Hospital of Philadelphia under Dr. C. Everett Koop. In 1974 he became an Epidemic IntelligenceService Officer (EIS), at the CDC, and a fellow in Preventive Medicine. He was a PAHO/CDC consultant forthe Brazilian government for the extensive meningococcal outbreaks of 1974/6, which was the origin ofhis publication recommending rifampin prophylaxis for contacts of patients with meningococcal diseasethat remain in effect today. In 1977 he went to West Africa to found the CDC Lassa fever Research Projectin Sierra Leone, where he received an emergency call to join the team investigating the first Ebolaepidemic in 1976 and again in 1979. In Sierra Leone he conducted de nitive studies of the epidemiologyand treatment of Lassa hemorrhagic fever, with a landmark publication in the New England Journal ofMedicine on effective antiviral treatment for this disease. He became Chief, Special Pathogens Branch,Division of Viral Diseases at the CDC in 1982, directing the Biosafety level 4 laboratories for 9 years. Hebecame involved in AIDS and led the original team that did the first AIDS investigation in Africa in 1983and played a key role in establishing the Project SIDA in Kinshasa, Zaire, and later, with Dr. DeCock and EISofficer with Dr. McCormick, the Project Retro Ci in Abidjan, Ivory Coast. In 1983 he identified the virusthat causes Hemorrhagic Fever with Renal Syndrome (Hantavirus) in his laboratory at CDC.

In 1993, he became Chairman, Community Health Sciences Department, at the Aga Khan UniversityMedical School (AKU) where he established an epidemiology program, resembling the CDC FieldEpidemiology Training Programs, and a Masters’ degree in Epidemiology. He returned to the US in 2001to start a new regional campus of the UT Houston School of Public Health in Brownsville, Texas.

His awards include the USPHS Meritorious Service Medal, and humanitarian awards from Florida SouthernCollege and Duke University Medical School, and Friend of Public Health award from the Texas DSHS. Dr.McCormick has over 250 scientific publications with co authors from over 20 different countries

PETER MELBY, MDDIREcToR, CENTER FOR TROPICAL DIsEAsEs, UNIVERSITY or TExAsMEDICAL BRANcH (UTMB)Dr. Peter Melby is Director of the Center for Tropical Diseases and Professor of Medicine, Microbiologyand Immunology, and Pathology at the University of Texas medical Branch (UTMB) in Galveston, Texas.Dr. Melby earned his MD degree with honors from the University of Colorado School of Medicine in 1983.He completed his residency at the University of Missouri Health Science Center in 1986, his researchfellowship at the Laboratory of Parasitic Diseases, NIAID, NIH in 1989 and his clinical fellowship inInfectious Disease at the University of Texas Health Science Center (UTHSCSA) in San Antonio in 1990.Prior to his position at UTMB he was Professor in the Department of Medicine at UTHSCSA and AssociateChief of Staff for Research and Development at the South Texas Veterans Health Care System.

Dr. Melby has a longstanding interest in tropical diseases and the neglected diseases of resource poordeveloping countries and has been involved in research in India, North Africa, Honduras, Colombia, Peruand Kenya. While at the UTHSCSA he received a Presidential teaching Award for his development ofcourses in Infectious Diseases and Tropical Medicine.

Dr. Melby’s research is focused on studies of immunity, pathogenesis, vaccine development and drugdiscovery for leishmaniasis. His work has led to better understanding of the determinants of immunityand molecular mechanisms related to the immunopathogenesis in leishmaniasis, in particular themechanisms of regulation of macrophage effector function in visceral leishmaniasis. He has alsoinvestigated the impact of malnutrition on innate immunity and visceral leishmaniasis, and ongoing workis focused on characterizing the mechanisms of impairment of lymph node function during polynutrientdeficiency. He has used several approaches to identify vaccine candidates for leishmaniasis, and has

defined vaccine efficacy in experimental infection models. He is particularly interested in the use ofvaccination to interrupt transmission from the reservoir host (dogs) to the insect vector (sand flies) inregions endemic for visceral leishmaniasis. Recent work in his lab has identified several new drugcandidates for cutaneous and visceral leishmaniasis.

SUE MONTGOMERY, MPH, DVM, CDREPIDEMIOLOGIST, CENTERs FOR DIsEAsE CONTROL AND PREVENTIONDr. Susan Montgomery is an epidemiologist at CDC in the Division of Parasitic Diseases and Malaria andserves as Lead of the Epidemiology Team in the Parasitic Diseases Branch. Her current responsibilitiesinclude coordinating activities related to Chagas disease and other neglected parasitic diseases in theUnited States. Dr. Montgomery’s primary research areas include Chagas disease and schistosomiasis. Herprevious positions at CDC were staff epidemiologist in the Foodborne and Diarrheal Diseases Branch andEIS officer with the Arboviral Diseases Branch in the Division of Vector Borne Infectious Diseases. Dr.Montgomery received her DVM from Cornell University in 1986 and MPH from Harvard School of PublicHealth in 2002.

KRIsTY O. MURRAY, PHDAssOcIATE PROFESSOR OF PEDIATRIcs, NATIONAL SCHOOL OFTROFIcAL MEDIcINE, BAYLOR COLLEGE OF MEDICINEDr. Kristy Murray is an Associate Professor of Pediatrics in the section of Pediatric Tropical Medicine atBaylor College of Medicine. She is also a member of the National School of Tropical Medicine.

Prior to joining the faculty at Baylor, Dr. Murray was an Associate Professor of Epidemiology for theCenter for Infectious Diseases at the University of Texas Health Science Center at Houston, School ofPublic Health (2002 2012). She received a Doctorate in Veterinary Medicine from Texas A&M Universityin College Station in 1998 and a PhD in Preventive Medicine and Community Health in ClinicalInvestigations from the University of Texas Medical Branch in Galveston.

Dr. Murray spent the rst five years of her career at the Centers for Disease Control and Prevention (CDC).At CDC, she served two years as an Epidemic Intelligence Service Officer conducting outbreakinvestigations, including the initial outbreak of West Nile virus in New York City in 1999, bubonic plague inWyoming, and unexplained illness and deaths in injection drug users in Ireland. She also had theopportunity to work on the polio eradication campaign in Bangladesh and research lyssaviruses in thePhilippines. She received several awards at CDC including the Secretary’s Award for Distinguished Servicefor her work on the West Nile virus Encephalitis Investigation Team and for the Anthrax InvestigationEmergency Response Team.

In 2002, Dr. Murray returned to Texas and joined the faculty at the University of Texas Health ScienceCenter at Houston. Her research over the past 10 years has been focused on vector borne and zoonoticdiseases, including West Nile virus, dengue, St. Louis encephalitis, eastern equine encephalitis virus, RockyMountain Spotted Fever, Chagas, and rabies. She has made numerous discoveries regarding healthoutcomes related to West Nile virus infection, including identifying persistent infection of the kidneys inpatients years past their initial infection, which has never before been reported. She teaches graduatelevel courses on epidemiology and infectious diseases, and advises master’s and PhD level students. Dr.Murray has received several awards for her work in academia, including the Innovation in Health ScienceEducation Award from the UT Academy of Health Science Education, Dean’s Award for TeachingExcellence, the UT Health Science Center Young Investigator Award, and the Texas A&M College ofVeterinary Medicine’s Distinguished Alumni Award. Dr. Murray serves on the editorial board of thejournal Epidemiology and Infection and has authored more than 40 scientific and technical papers.

]EsUs VALENZUELA, PHDCHIEF, VECTOR MOLEcULAR BIOLOGY SEGTION, NATIONALINsTITUTEs OF HEALTHDr. Jesus Valenzuela has over 15 years of experience studying vector proteins and in the past few yearsmore focus in the study of the molecular interactions between the vector, the pathogen and the host. Themodel insect he studies is the sand fly; however, Dr. Valenzuela has very productive collaborations withother laboratories studying mosquitoes, fleas, kissing bugs and ticks. His laboratory focuses on themolecular aspects of sand fly salivary and midgut proteins with emphasis on the understanding ofvector/host and vector/parasite interactions, specifically sand fly/Leishmania interactions. Unit researchcombines basic approaches together with veterinary and clinical research broadening our understandingof the relationship between immune responses to vector proteins in animal reservoirs and humans anddisease outcome, and between the Leishmania parasite and the sand fly midgut proteins to ultimatelydevelop a vector based vaccine against the neglected disease leishmaniasis.

The laboratory has also become a collaboration center for many laboratories for the study of vectorsalivary and midgut proteins using transcriptomic approaches, the production of recombinant proteinsusing a mammalian expression system and the production of antibodies to vector and parasite proteinsusing a protocol involving intradermal immunization of the DNA plasmid that was developed by the unit.The success of these approaches in the study of vector and parasite proteins resulted in collaborationswith laboratories at the LMVR, LPD and LIG, universities in the US and worldwide including seven differentlaboratories from Brazil, two from the Czech Republic, one from Japan, and one from Scotland. The unithas hosted principal investigators, post doctoral fellows and graduate students from these laboratoriesfor training on these approaches over the last eight years.

RESEARCH !AIviERIcA

1101 KING STREET, SUITE 520ALEXANDRIA, VA 22314 2960

703 739 2577 (PHONE)703 739 2372 (FAX)

[email protected]